Related Experiment Video

Updated: Jan 18, 2026

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.6K

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

Hans-Peter Hammes1, Xueliang Du, Diane Edelstein

  • 1Medical Clinic V, School of Clinical Medicine, Mannheim, Germany.

Nature Medicine
|February 20, 2003
PubMed

Insights

Benfotiamine, a thiamine derivative, effectively inhibits key pathways contributing to diabetic vascular damage by activating transketolase. This discovery offers a potential therapeutic strategy for preventing diabetic complications.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Hyperglycemia-induced vascular damage involves the hexosamine, advanced glycation end product (AGE), and diacylglycerol (DAG)-protein kinase C (PKC) pathways.
  • These pathways are activated by increased glyceraldehyde-3-phosphate and fructose-6-phosphate availability.

Purpose of the Study:

  • To investigate the potential of benfotiamine in inhibiting hyperglycemia-induced biochemical pathways and preventing diabetic vascular complications.
  • To elucidate the mechanism by which benfotiamine exerts its effects.

Main Methods:

  • Utilized animal models of diabetic retinopathy.
  • Administered benfotiamine to assess its impact on key biochemical pathways and NF-kappaB activation.
  • Measured the activity of transketolase and the levels of pathway metabolites.

Main Results:

  • Benfotiamine inhibited the hexosamine, AGE, and DAG-PKC pathways by activating transketolase.
  • Benfotiamine reduced hyperglycemia-associated NF-kappaB activation in diabetic animal retinas.
  • Benfotiamine treatment prevented experimental diabetic retinopathy in animal models.

Conclusions:

  • Benfotiamine demonstrates a multi-targeted inhibitory effect on pathways driving diabetic vascular damage.
  • Activation of transketolase by benfotiamine is a key mechanism for its protective effects.
  • Benfotiamine holds clinical promise for preventing and managing diabetic complications.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

5.2K
Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

14.0K

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
526
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
870